Active disease requiring TNF-alpha-antagonist therapy can be well discriminated with different ASDAS sets: A prospective, follow-up of disease activity assessment in ankylosing spondylitis

Clinical and Experimental Rheumatology

Volumn 28, Issue 5, 2010, Pages 752-755

  Aydin, S Z ^a,b   Can, M ^b   Atagunduz, P ^b   Direskeneli, H ^b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b MARMARA UNIVERSITY   (Turkey)

Author keywords

Ankylosing spondylitis; ASDAS; Disease activity assessment

Indexed keywords

ANTIRHEUMATIC AGENT; C REACTIVE PROTEIN; HLA B27 ANTIGEN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTAGONIST; UNCLASSIFIED DRUG;

ACUTE PHASE RESPONSE; ADULT; ANKYLOSING SPONDYLITIS; ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE; ARTHRALGIA; ARTHRITIS; ARTICLE; BACKACHE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DIAGNOSTIC TEST; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE INCREASE; ENTHESITIS; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; FEMALE; FOLLOW UP; HUMAN; JOINT SWELLING; MAJOR CLINICAL STUDY; MALE; MORNING STIFFNESS; PERIPHERAL ARTHRITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; STANDARD;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DISABILITY EVALUATION; FOLLOW-UP STUDIES; HEALTH STATUS; HUMANS; PROGNOSIS; PROSPECTIVE STUDIES; QUALITY OF LIFE; ROC CURVE; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78650581154     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. GARRETT S, JENKINSØN T, KENNEDY LG, WHITELOCK H, GAISFORD P, CALIN A: A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
2. SPOORENBERG A, VAN TUBERGEN A, LANDEWE R et al.: Measuring disease activity in ankylosing spondylitis: patient and physician have different perspectives. Rheumatology 2005;44:789-95.
3. KALDEN JR: Biologies in the treatment of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009;27(Suppl. 55):164-7.
4. LUKAS C, LANDEWE R, SIEPER J et al.: Assessment of SpondyloArthritis international Society. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:18-24.
5. HEIBERG MS, NORDVÅG B-Y, MIKKELSEN K et al.: The comparative effectiveness of tumor necrosing factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis. A six-month, longitudinal, observational, multicenter study. Arthritis Rheum 2005;52:2506-12.
6. VAN der HEUDE D, LIE E, KVIEN TK et al.: The ASDAS is a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:1811-8.
7. PEDERSEN SJ, SØRENSEN IJ, HERMANN KG et al.: Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS), and clinical and magnetic resonance imaging measures of disease activity in a 1 year follow-up study of patients with axial spondylarthritis treated with TNF-alpha inhibitors. Ann Rheum Dis 2010;69:1065-71.
8. VAN der LINDEN S, VALKENBURG HA, CATS A: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.